ArticleNature communications2023

A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity.

Li Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.